Arrakis Therapeutics Inc. told multiple prospective partners in recent years that it wasn’t interested in research collaborations yet, but the time finally came for the privately held firm on 8 April as it signed a discovery pact with Roche covering the range of therapeutic areas the Swiss pharma focuses on.
Arrakis CEO Michael Gilman told Scrip that the company will apply its RNA-targeted small molecule technology to Roche-specified targets covering...
Welcome to Scrip
Create an account to read this article
Already a subscriber?